Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Partners with AstraZeneca on Prostate Cancer Targets

NEW YORK, Nov. 1 (GenomeWeb News) - Caprion and AstraZeneca will collaborate to develop therapies for prostate cancer, Caprion Pharmaceuticals said today.

 

Under the agreement, AstraZeneca will evaluate prostate cancer drug targets discovered by Caprion and obtain exclusive, worldwide rights to develop and commercialize therapeutic applications for selected targets. Caprion will retain rights to other targets.

 

AstraZeneca will pay Caprion an unspecified amount for up-front payment and license fees. The company will make additional payments contingent on its meeting certain development and commercialization milestones.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.